# Clinical Study of 68Ga Labeled HER2 Affibody Analogues

> **NCT05411432** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 56 (estimated)

## Conditions studied

- HER2-positive Breast Cancer and Gastric Cancer

## Interventions

- **DRUG:** 68Ga labeled HER2 Affibody

## Key facts

- **NCT ID:** NCT05411432
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411432, "Clinical Study of 68Ga Labeled HER2 Affibody Analogues". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05411432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*